A Randomized Placebo Controlled Study of OSI-774 (Erlotinib HCl, Tarceva[TM]) in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease

Criterios de inclusión

• Clinical diagnosis of stage IIIB or IV non-small cell lung cancer.
• Must have evidence of disease (clinical or radiological).
• Have failed 1 but no more than 2 prior chemotherapy regimens, have recovered from any side effects and have not had any chemotherapy for at least 21 days.
• If the patient has had surgery, the surgery was at least 2 weeks ago.
• Patients whose cancer has spread to their brain or central nervous system are eligible, providing that they have been on stable dose of steroids for at least 4 weeks and are free of symptoms.
• If the patient received radiation therapy, treatment was at least 4 weeks ago.